CP, biopharm: Wook, you stated[in post #280622]: "As Dr. Wolchok answered when describing the Back trial...it's black and white and only time will tell the true colors of Phosphatidylserine Targeting and Manipulation."
To clarify some December 7, 2016 Wistar proceedings relating to PPHM and mch1N11....
I had asked a 2nd question of Dr. Wolchok: "Do you have any color you can currently add to the slide presented at SITC by your MSK team[he and I had earlier been referring to the Budhu et al slide forming an integral part of CJG's post # 278797 above in stickies] from additional clinical trials?"
Dr Wolchok answered[per my memory]:"Today, I am black and white, no color, on that question and slide." I had no chance to follow up on that Q&A, but took his response to mean 1) no comment, or 2) no further trial contains enough data/results that would allow him to give an informed answer with further "color."
For context, I had 1st asked Dr Wolchok the question in CP's post # 280118 verbatim, reading it from the printed copy I took with me to Wistar[see # 280118].
"Will tumour environment conditioning through Phosphatidylserine targeting become a combination ingredient needed to allow most new immuno-therapy treatments to benefit from an activated immune system and achieve better results or larger responder foot-prints?"
Dr Wolchok answered/opined that the pre-clinical work did support a "yes" answer to that question. By way of introduction, I had directed his attention to the SITC slide above. He went as far as pulling a slide from his power-point presentation that featured a photograph of his laboratory staff and colleagues to identify for us conference attendees who Budhu is.
More later on the Wistar conference in general, and other conversations I had with Dr. Wolchok, both pre-conference as well as post-conference.
asmarterwookie, you are welcome!! We will discuss the rest of the day later.
I am going to investigate the possibility of obtaining Dr. Wolchok's power-point and audio presentation.
